

chain nodes :  
 6 7 10 11 12 13 15 17 18  
 ring nodes :  
 1 2 3 4 5  
 chain bonds :  
 4-6 5-10 10-11 11-12 12-13 13-15 13-17 17-18  
 ring bonds :  
 1-2 1-5 2-3 3-4 4-5  
 exact/norm bonds :  
 1-5 4-5 4-6 13-15 13-17 17-18  
 exact bonds :  
 1-2 2-3 3-4 5-10 10-11 11-12 12-13  
 isolated ring systems :  
 containing 1 :

G1:H,Ak

G2:C,SO2

Match level :  
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:CLASS 10:CLASS 11:CLASS 12:CLASS  
 13:CLASS 15:CLASS 17:CLASS 18:Atom  
 Generic attributes :  
 7:  
 Saturation : Unsaturated  
 Number of Carbon Atoms : 7 or more  
 Type of Ring System : Polycyclic

Element Count :  
 Node 7: Limited  
 C,C8-9  
 N,N1-2  
 O,OO  
 S,SO

=>  
Uploading C:\Program Files\Stnexp\Queries\10537034.str



```

chain nodes :
6 7 10 11 12 13 15 17 18
ring nodes :
1 2 3 4 5
chain bonds :
4-6 5-10 10-11 11-12 12-13 13-15 13-17 17-18
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-5 4-5 4-6 13-15 13-17 17-18
exact bonds :
1-2 2-3 3-4 5-10 10-11 11-12 12-13
isolated ring systems :
containing 1 :

```

G1:H,Ak

G2:C,SO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:CLASS 10:CLASS

11:CLASS 12:CLASS 13:CLASS 15:CLASS 17:CLASS 18:Atom

Generic attributes :

7:

Saturation : Unsaturated

Number of Carbon Atoms : 7 or more

Type of Ring System : Polycyclic

Element Count :

Node 7: Limited

C,C8-9

N,N1-2

O,OO


S,SO

L1 STRUCTURE UPLOADED

=&gt; d 11

L1 HAS NO ANSWERS

L1 STR



G1 H,Ak

G2 C,SO2

Structure attributes must be viewed using STN Express query preparation.

```
=> s 11 sss sam
SAMPLE SEARCH INITIATED 08:52:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 119 TO ITERATE

100.0% PROCESSED 119 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1726 TO 3034
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> => s 11 sss ful
FULL SEARCH INITIATED 08:53:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2438 TO ITERATE


100.0% PROCESSED 2438 ITERATIONS 32 ANSWERS
SEARCH TIME: 00.00.01

L3 32 SEA SSS FUL L1


=> => s 13
L4 2 L3

=> d 14 1-2 bib,ab,hitstr
```

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:228853 CAPLUS  
 DN 146:462163  
 TI Oxazolidinones as novel human CCR8 antagonists  
 AU Jin, Jian; Wang, Yonghui; Wang, Feng; Kerns, Jeffery K.; Vinader, Victoria  
     M.; Hancock, Ashley P.; Lindon, Matthew J.; Stevenson, Graeme I.; Morrow,  
     Dwight M.; Rao, Parvathi; Nguyen, Cuc; Barrett, Victoria J.; Browning,  
     Chris; Hartmann, Guido; Andrew, David P.; Sarau, Henry M.; Foley, James  
     J.; Jurewicz, Anthony J.; Fornwald, James A.; Harker, Andy J.; Moore,  
     Michael L.; Rivero, Ralph A.; Belmonte, Kristen E.; Connor, Helen E.  
 CS Discovery Medicinal Chemistry, Molecular Discovery Research,  
     GlaxoSmithKline, Collegeville, PA, 19426, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2007), 17(6), 1722-1725  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 146:462163  
 AB High-throughput screening of the corporate compound collection led to the  
     discovery of a novel series of N-substituted-5-aryl-oxazolidinones, e.g.,  
     I, as potent human CCR8 antagonists. The synthesis, structure-activity  
     relationships, and optimization of the series that led to the  
     identification of I (SB-649701), are described.  
 IT 935263-04-0P 935263-05-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
     (Biological study); PREP (Preparation)  
     (preparation, CCR8 antagonistic activity, and SAR of aryloxazolidinones)  
 RN 935263-04-0 CAPLUS  
 CN 2-Oxazolidinone, 3-[3-[(1H-indol-2-ylmethyl)amino]propyl]-5-(6-methoxy-4-  
     quinolinyl)- (CA INDEX NAME)



RN 935263-05-1 CAPLUS  
 CN 2-Oxazolidinone, 3-[3-[(1H-indol-2-ylmethyl)methylamino]propyl]-5-(6-  
     methoxy-4-quinolinyl)- (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:486385 CAPLUS  
 DN 141:54319  
 TI Preparation of quinolines and naphthyridine derivatives for use in pharmaceutical compositions as antibacterial agents  
 IN Axten, Jeffrey Michael; Dartois, Catherine Genevieve Yvette; Nadler, Guy Marguerite Marie Gerard; Pearson, Neil David  
 PA Glaxo Group Limited, UK  
 SO PCT Int. Appl., 46 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

Applicant's

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050036	A2	20040617	WO 2003-US38444	20031203
	WO 2004050036	A3	20040902		
	W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003294565	A1	20040623	AU 2003-294565	20031203
	EP 1567520	A2	20050831	EP 2003-787253	20031203
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006515862	T	20060608	JP 2004-571000	20031203
	US 2006116512	A1	20060601		20050601
PRAI	US 2002-430908P	P	20021204		
	US 2003-469602P	P	20030507		
	WO 2003-US38444	W	20031203		
OS	MARPAT 141:54319				
AB	Quinolinyl and naphthyridinyl substituted oxazolidinones, such as I [R = substituted or unsubstituted quinolinyl or naphthyridinyl; R2 = H, OH, NH2, alkyl, alkoxy; R3 = H, alkyl; R4 = aryl, heteroaryl; X = -CH2-, -CO-, -SO2-], were prepared for therapeutic use in the treatment of bacterial infections. Thus, oxazolidinone II was prepared via a series of synthetic steps which included conversion of 6-methoxyquinoline-4-carboxylic acid to 6-methoxy-4-(2R)-oxiranylquinoline (III), reaction of III with H2N(CH2)3NHCO2CMe3 and subsequent cyclocondensation of the resulting aminoalc. with triphosgene to form the oxazolidinone ring, removal of the amine BOC protecting group and, finally sulfenylation of the resulting amine with 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-sulfonyl chloride to form the desired oxazolidinone II. The prepared oxazolidinones were assayed for antibacterial activity against organisms, such as <i>Staphylococcus epidermidis</i> , <i>Streptococcus pneumoniae</i> , <i>S. pyogenes</i> , <i>Enterococcus faecalis</i> , <i>E. faecium</i> , <i>Haemophilus influenzae</i> , <i>Moraxella catarrhalis</i> and <i>Escherichia coli</i> .				
IT	706809-25-8P	706809-29-2P	706809-30-5P		
	706809-31-6P	706809-32-7P	706809-37-2P		
	706809-38-3P	706809-39-4P	706809-40-7P		
	706809-43-0P	706809-47-4P	706809-48-5P		
	706809-49-6P	706809-50-9P	706809-51-0P		
	706809-52-1P	706809-53-2P	706809-54-3P		

706809-55-4P 706809-62-3P 706809-65-6P

706809-67-8P 706809-68-9P 706809-69-0P

706809-77-0P 706809-78-1P 706809-79-2P

706809-80-5P 706809-81-6P 706809-82-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinolinyl and naphthyridinyl substituted oxazolidinones for therapeutic use as antibacterial agents)

RN 706809-25-8 CAPLUS

CN 2H-1,4-Benzothiazine-6-sulfonamide, 3,4-dihydro-N-[3-[(5R)-5-(6-methoxy-4-quinolinyl)-2-oxo-3-oxazolidinyl]propyl]-3-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-29-2 CAPLUS

CN 1,5-Benzothiazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-[3-[(5R)-5-(6-methoxy-4-quinolinyl)-2-oxo-3-oxazolidinyl]propyl]-3-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 706809-30-5 CAPLUS

CN 2H-1,4-Benzoxazine-6-sulfonamide, 3,4-dihydro-N-[3-[(5R)-5-(6-methoxy-4-

quinolinyl)-2-oxo-3-oxazolidinyl]propyl]-3-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-31-6 CAPLUS

CN 2H-1,4-Benzothiazine-6-sulfonamide, 7-chloro-3,4-dihydro-N-[3-[(5R)-5-(6-methoxy-4-quinolinyl)-2-oxo-3-oxazolidinyl]propyl]-3-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-32-7 CAPLUS

CN 2H-1,4-Benzothiazine-6-sulfonamide, N-[3-[(5R)-5-(8-fluoro-6-methoxy-4-quinolinyl)-2-oxo-3-oxazolidinyl]propyl]-3,4-dihydro-3-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-37-2 CAPLUS

CN 2H-1,4-Benzothiazine-6-sulfonamide, 3,4-dihydro-N-[3-[(5R)-5-(6-methoxy-1,5-naphthyridin-4-yl)-2-oxo-3-oxazolidinyl]propyl]-3-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-38-3 CAPLUS

CN 2H-1,4-Benzothiazine-6-sulfonamide, 3,4-dihydro-N-[3-[(5S)-5-(6-methoxy-1,5-naphthyridin-4-yl)-2-oxo-3-oxazolidinyl]propyl]-3-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-39-4 CAPLUS

CN 2H-1,4-Benzoxazine-6-sulfonamide, 3,4-dihydro-N-[3-[(5R)-5-(6-methoxy-1,5-naphthyridin-4-yl)-2-oxo-3-oxazolidinyl]propyl]-3-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-40-7 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-thiazine-6-carboxamide, 3,4-dihydro-N-[3-[(5R)-5-(6-methoxy-4-quinolinyl)-2-oxo-3-oxazolidinyl]propyl]-3-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-43-0 CAPLUS

CN 2-Oxazolidinone, 3-[3-[(1H-indol-2-ylmethyl)methylamino]propyl]-5-(6-methoxy-4-quinolinyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-47-4 CAPLUS

CN 2-Oxazolidinone, 3-[3-[(2,1,3-benzothiadiazol-5-ylmethyl)amino]propyl]-5-(6-methoxy-4-quinolinyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-48-5 CAPLUS

CN 2-Oxazolidinone, 3-[3-[(1H-indol-2-ylmethyl)amino]propyl]-5-(6-methoxy-4-quinolinyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-49-6 CAPLUS

CN 2-Oxazolidinone, 3-[3-[(8-hydroxy-2-quinoliny)methyl]methylamino]propyl]-5-(6-methoxy-4-quinolinyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-50-9 CAPLUS

CN 2-Oxazolidinone, 3-[3-[(4-fluoro-1H-benzimidazol-2-yl)methyl]amino]propyl]-5-(6-methoxy-4-quinolinyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-51-0 CAPLUS

CN 2H-1, 4-Benzoxazin-3(4H)-one, 6-[[3-[(5R)-5-(6-methoxy-4-quinoliny)-2-oxo-3-oxazolidinyl]propyl]amino]methyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 706809-52-1 CAPLUS

CN 2-Oxazolidinone, 3-[3-[(8-hydroxy-2-quinoliny) methyl]amino]propyl]-5-(6-methoxy-4-quinoliny)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-53-2 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[[3-[(5R)-5-(6-methoxy-4-quinoliny)-2-oxo-3-oxazolidinyl]propyl]amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 706809-54-3 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[3-[(5R)-5-(6-methoxy-4-quinoliny)-2-oxo-3-oxazolidinyl]propyl]amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 706809-55-4 CAPLUS

CN 2H-Pyrido[3,2-b]1,4-oxazin-3(4H)-one, 6-[[[3-[(5R)-5-(8-fluoro-6-methoxy-4-quinolinyl)-2-oxo-3-oxazolidinyl]propylamino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A


● 2 HCl

RN 706809-62-3 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-sulfonamide, 3,4-dihydro-N-[3-[(5R)-5-(6-methoxy-1,5-naphthyridin-4-yl)-2-oxo-3-oxazolidinyl]-2,2-dimethylpropyl]-3-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 706809-65-6 CAPLUS  
 CN 1,4-Benzodioxin-6-sulfonamide, 2,3-dihydro-N-[3-[5-(6-methoxy-1,5-naphthyridin-4-yl)-2-oxo-3-oxazolidinyl]propyl]- (CA INDEX NAME)




RN 706809-67-8 CAPLUS  
 CN 2H-Pyrido[3,2-b]-1,4-thiazin-3(4H)-one, 6-[[3-[5-(6-methoxy-1,5-naphthyridin-4-yl)-2-oxo-3-oxazolidinyl]propyl]amino]methyl]- (CA INDEX

NAME)

PAGE 1-A




PAGE 2-A




RN 706809-68-9 CAPLUS  
 CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[[3-[5-(6-methoxy-1,5-naphthyridin-4-yl)-2-oxo-3-oxazolidinyl]propyl]amino]methyl]- (CA INDEX  
 NAME)

PAGE 1-A




PAGE 2-A



RN 706809-69-0 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-sulfonamide, 3,4-dihydro-N-[(2R)-2-hydroxy-3-[(5R)-5-(6-methoxy-1,5-dihydro-4H-pyridin-4-yl)-2-oxo-3-oxazolidinyl]propyl]-3-oxo-  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-77-0 CAPLUS

CN 2H-Pyrido[3,2-b]1,4-thiazin-3(4H)-one, 6-[[[(2S)-2-hydroxy-3-[(5R)-5-(6-methoxy-1,5-naphthyridin-4-yl)-2-oxo-3-oxazolidinyl]propyl]amino]methyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 706809-78-1 CAPLUS

CN 2H-1,4-Benzothiazine-6-sulfonamide, 3,4-dihydro-N-[(2S)-2-hydroxy-3-[(5R)-5-(6-methoxy-1,5-naphthyridin-4-yl)-2-oxo-3-oxazolidinyl]propyl]-3-oxo-(CA INDEX NAME)


Absolute stereochemistry.



RN 706809-79-2 CAPLUS

CN 2H-Pyrido[3,2-b]1,4-thiazin-3(4H)-one, 6-[[[(2R)-2-hydroxy-3-[(5R)-5-(6-methoxy-1,5-naphthyridin-4-yl)-2-oxo-3-oxazolidinyl]propyl]amino]methyl]-(CA INDEX NAME)


Absolute stereochemistry.



RN 706809-80-5 CAPLUS

CN 1,5-Benzothiazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-[3-[(5R)-5-(6-methoxy-4-quinolinyl)-2-oxo-3-oxazolidinyl]propyl]-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-81-6 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[3-[(5R)-5-(6-methoxy-4-quinolinyl)-2-oxo-3-oxazolidinyl]propyl]amino]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 706809-82-7 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[3-[(5R)-5-(8-fluoro-6-methoxy-4-quinolinyl)-2-oxo-3-oxazolidinyl]propyl]amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



10/537,034

=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	11.38	190.41
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

STN INTERNATIONAL LOGOFF AT 08:53:50 ON 30 MAR 2008